Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.63
$0.04(5.74%)
At close: 4:00 PM EDT
$0.63
$0.04(5.74%)
Day’s Range― - ―
52-Week Range$0.59 - $1,030.00
Previous Close$0.68
Volume76.44K
Average Volume (3M)1.94M
Market Cap
$15.86M
Enterprise Value-$7.10
Total Cash (Recent Filing)$7.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.86
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,339,787
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEliminating debt reduces interest and refinancing pressure, giving Kala Bio a cleaner capital structure than in prior years. Positive equity also provides some protection against liabilities, although the relatively small asset base limits the overall cushion.
Loss ReductionThe smaller TTM loss suggests some progress in controlling expenses or reducing operating losses. If sustained, this could extend liquidity and lower future financing needs, though the company remains materially unprofitable and has not established a path to break-even.
Access To Capital MarketsThe filing confirms that Kala Bio retains an established mechanism to raise capital for operations and strategic initiatives. This financing access may improve near-term execution flexibility, although it does not replace the need to develop sustainable operating cash flows.
Bears Say
Near-zero Revenue BaseA near-zero revenue base indicates that Kala Bio currently lacks meaningful commercial scale or recurring product monetization. Without revenue growth, the company cannot reliably fund research, development, or corporate costs internally, leaving long-term performance dependent on successful commercialization.
Persistent Cash BurnSustained negative cash generation is a fundamental liquidity risk because ongoing operations consume capital rather than produce it. Even though burn improved from approximately -$32.0M in 2025, continued spending will likely require additional financing if operating cash flow does not improve.
Dependence On External FinancingKala Bio’s lack of identified recurring revenue, monetized products, or material licensing income leaves external capital as the principal funding route. Repeated financing dependence can constrain strategy, expose shareholders to dilution, and increase execution risk if capital access weakens.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.59 and its highest was $1030.00 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $15.86M.
When is KALA BIO’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KALA BIO’s earnings last quarter?
Currently, no data Available
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 19,339,787 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Citius Pharmaceuticals
―
Lexaria Bioscience
―
Exicure
―
Ownership Overview
3.47% Insiders
0.34% Mutual Funds
― Other Institutional Investors
95.05% Public Companies and
Individual Investors